Syndax Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SNDX research report →
Companywww.syndax.com
Syndax Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD).
- CEO
- Michael A. Metzger
- IPO
- 2016
- Employees
- 270
- HQ
- New York City, MA, US
Price Chart
Valuation
- Market Cap
- $1.79B
- P/E
- -7.18
- P/S
- 8.23
- P/B
- 41.97
- EV/EBITDA
- -12.31
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 97.96%
- Op Margin
- -102.93%
- Net Margin
- -112.01%
- ROE
- -256.66%
- ROIC
- -57.76%
Growth & Income
- Revenue
- $172.35M · 627.84%
- Net Income
- $-285,422,000 · 10.46%
- EPS
- $-3.29 · 11.80%
- Op Income
- $-273,084,000
- FCF YoY
- -17.56%
Performance & Tape
- 52W High
- $25.59
- 52W Low
- $8.59
- 50D MA
- $22.69
- 200D MA
- $19.06
- Beta
- 0.41
- Avg Volume
- 1.59M
Get TickerSpark's AI analysis on SNDX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 9, 26 | Metzger Michael A | sell | 17,159 |
| Feb 9, 26 | Goldan Keith A. | sell | 3,410 |
| Feb 4, 26 | Metzger Michael A | other | 144,600 |
| Feb 6, 26 | Metzger Michael A | sell | 7,412 |
| Feb 4, 26 | Metzger Michael A | other | 440,000 |
| Feb 4, 26 | Metzger Michael A | other | 73,000 |
| Feb 4, 26 | Goldan Keith A. | other | 30,750 |
| Feb 6, 26 | Goldan Keith A. | sell | 2,082 |
| Feb 4, 26 | Goldan Keith A. | other | 118,000 |
| Feb 4, 26 | Goldan Keith A. | other | 21,500 |
Our SNDX Coverage
We haven't published any research on SNDX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SNDX Report →